Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Oruka Therapeutics, Inc.

NASDAQ: ORKA · Life Sciences · 12 alerts · CIK 907654

Share price
$99.24Close, Nov 16
Market cap
$6.73B
Shares outstanding
67.82MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Oruka Therapeutics, Inc. filings on SEC EDGAR ↗

6:44 PM ET Form 4
Insider Selling

Oruka Therapeutics CMO Joana Goncalves Sells $707K of Stock

Joana Goncalves, CMO, sold 7,000 shares of Oruka Therapeutics, Inc. at $99.52 to $105.86 a share (average $100.96) in 6 transactions, worth $707K in total on Nov 16, 2026. Shares held after the trade: 31,771 (-1.5%).

Value
$707K
Shares
7,000
Average price
$100.96
Role
CMO
Holding change
-1.5%
Trade date
Nov 16, 2026
8:04 PM ET Form 4
Insider Selling

Oruka Therapeutics SVP, Finance Arjun Agarwal Sells $1.05M of Stock

Arjun Agarwal, SVP, Finance, sold 10,000 shares of Oruka Therapeutics, Inc. at $101.98 to $107.00 a share (average $104.97) in 6 transactions, worth $1.05M in total on Nov 12, 2026. Shares held after the trade: 14,219 (-0.7%).

Value
$1.05M
Shares
10,000
Average price
$104.97
Role
SVP, Finance
Holding change
-0.7%
Trade date
Nov 12, 2026
8:00 PM ET Form 4
Insider Selling

Oruka Therapeutics Insider Kristine M. Ball Sells $1.89M of Stock

Kristine M. Ball sold 18,000 shares of Oruka Therapeutics, Inc. at $102.10 to $106.98 a share (average $104.93) in 6 transactions, worth $1.89M in total on Nov 12, 2026. Shares held after the trade: 0 (-100.0%).

Value
$1.89M
Shares
18,000
Average price
$104.93
Holding change
-100.0%
Trade date
Nov 12, 2026
4:03 PM ET 10-Q
Financial Results

Oruka Therapeutics Q3 2026 Results: Net Loss of $50M, Loss Widens

Oruka Therapeutics reported a net loss of $123.0 million for the nine months ended September 30, 2026, driven by $126.1 million in research and development expenses. The company significantly strengthened its balance sheet during the period, ending with $1.23 billion in total assets following a major common stock offering in April 2026 and ATM program activity.

Key figure
Net loss $50M
5:47 PM ET Form 4
Insider Selling

Oruka Therapeutics CEO Lawrence Otto Klein Sells $2.39M of Stock

Lawrence Otto Klein, CEO, sold 25,000 shares of Oruka Therapeutics, Inc. at $94.77 to $98.40 a share (average $95.60) in 5 transactions, worth $2.39M in total on Nov 2, 2026. Shares held after the trade: 923,128 (-0.0%).

Value
$2.39M
Shares
25,000
Average price
$95.60
Role
CEO
Holding change
-0.0%
Trade date
Nov 2, 2026
8:01 AM ET 8-K
Clinical Trial Data

Oruka Therapeutics Clinical Trial Data

Oruka Therapeutics announced positive Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001 in patients with moderate-to-severe plaque psoriasis. The trial met its primary endpoint with 61% of patients in the high-dose (600 mg) group achieving complete skin clearance (PASI 100) compared to 0% for placebo, supporting the planned initiation of Phase 3 trials in the first half of 2027.

8:42 PM ET Form 4
Insider Selling

Oruka Therapeutics General Counsel Paul T. Quinlan Sells $707K of Stock

Paul T. Quinlan, General Counsel, sold 9,000 shares of Oruka Therapeutics, Inc. at $74.90 to $79.49 a share (average $78.53) in 5 transactions, worth $707K in total on Oct 20, 2026. Shares held after the trade: 29,995 (-9.1%).

Value
$707K
Shares
9,000
Average price
$78.53
Role
General Counsel
Holding change
-9.1%
Trade date
Oct 20, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.